Local Minocycline in Patients Under Supportive Periodontal Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

June 3, 2016

Primary Completion Date

October 18, 2019

Study Completion Date

October 18, 2019

Conditions
Periodontitis
Interventions
DRUG

2% minocycline hydrochloride controlled-delivery system (MHS)

The test product is a highly viscous gel for local subgingival placement composing of an ointment containing micro-capsule type particles for sustained release and the active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan). The other ingredients include magnesium chloride, hydroxyl-ethylcellulose, aminoalkylmethacrylaye copolymer, triacetin and concentrated glycerine, giving the preparation a sustained-released property. It will be applied to experimental teeth and the adjacent teeth by gently inserting the tip of a specially designed applicator until the paste flows over the gingival margin.

DRUG

Placebos

It is the same gel as MHS but without active ingredient minocycline hydrochloride.

All Listed Sponsors
lead

National Dental Centre, Singapore

OTHER

NCT04036890 - Local Minocycline in Patients Under Supportive Periodontal Therapy | Biotech Hunter | Biotech Hunter